Medical/Pharmaceuticals

CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets

SEOUL, South Korea, Oct. 28, 2026 /PRNewswire/ -- CELSET INC., a Korean biotechnology company specializing in medical aesthetics, has launched SOLTOX, its botulinum toxin type A brand, introducing a Korean botulinum toxin brand to the international medical aesthetics industry.

2026-10-28 16:00 2873

Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment

SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and multidisciplinary expertise to serve patients from China and abroad. The center was unveiled at the inaugural Jiahui International Cell The...

2026-10-28 14:41 2407

The Jumbophage Cocktail_Fighting Superbugs and Shrimp Disease

BANGKOK, Oct. 28, 2026 /PRNewswire/ -- What if a weapon against some of the world's most stubborn bacteria were hiding in the soil beneath our feet? Could these microscopic hunters help us confront antibiotic-resistant "superbugs" and bacterial diseases devastating shrimp? The answer may lie in u...

2026-10-28 14:24 3473

Docquity Extends Asian Healthcare Intelligence to the Middle East Through Strategic Partnership with Growth Partner Holding

Saudi Arabia launch opens the region, with expansion planned into Egypt, Turkey, Jordan and Iraq; Ask Dx is the core platform RIYADH, Saudi Arabia and SINGAPORE, Oct. 28, 2026 /PRNewswire/ -- Docquity, the clinical AI platform for more than 500,000 verified doctors across Asia, today announced a...

2026-10-28 13:40 3876

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clin...

2026-10-28 08:00 4335

Fosun Health Makes Historic Debut at Canton Fair, Foshan Fosun Chancheng Hospital Showcases International Healthcare Services

GUANGZHOU, China, Oct. 28, 2026 /PRNewswire/ -- Fosun Health has become the first cross-border international healthcare group to exhibit at the Canton Fair in its 70-year history, debuting at the event's inaugural International Healthcare Zone alongside four Greater Bay Area (GBA) hospitals, incl...

2026-10-28 08:00 5121

How to Care for Caregivers? NCCN Debuts Essential Guide for Supporting Loved Ones with Cancer

New, free book offers simple but empowering information on how to care for people with cancer while also caring for yourself. PLYMOUTH MEETING, Pa., Oct. 27, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States ...

2026-10-27 20:07 2909

Natus Celebrates Grand Opening of Suzhou Facility - Advancing Innovation in China, for China

Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China SUZHOU, China, Oct. 27, 2026 /PRNewswire/ -- Natus Medical Incorporated, the world's largest pure-play neurodiagnostic company, today celebrated the grand opening of its devel...

2026-10-27 11:13 3025

Asia-Pacific's First Whole-Body Clinical 5T MRI System Installed in Vietnam, Advancing a New Regional High-Field MRI Center of Excellence

HANOI, Vietnam, Oct. 27, 2026 /PRNewswire/ -- On October 26, 2026, United Imaging Healthcare's uMR Jupiter 5T MRI system was officially introduced at Hanoi Medical University Hospital (HMUH), marking the arrival ofthe first whole-body clinical 5T MRI in the Asia-Pacificregion (outside China). The...

2026-10-27 10:20 4892

Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology

CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis o...

2026-10-26 18:33 3892

CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is metabolised very differently in the body. Research into fructose metabolism and its regulation of metabolism in the human body has in recent ye...

2026-10-26 17:50 2533

Tencent Cloud Enhances Telehealth Experiences for Care, Safeguarding Every Doctor-Patient Connection

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology company Tencent, today announced its collaboration with Care, one of Singapore's leading and most trusted telehealth digital solutions providers, to strengthen the quality and reliability of virtual he...

2026-10-26 16:57 1901

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumors Highlights * Three pillars of clinical validation: Clinical data from ov...

2026-10-26 16:45 2136

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. - ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), support...

2026-10-26 08:10 6746

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-10-26 08:00 2876

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

* Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). * The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median follow-u...

2026-10-25 19:12 4981

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

* PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two groups, respectively. * Responses were more dur...

2026-10-25 18:44 6198

Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked a m...

2026-10-24 19:38 7433

Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 ...

2026-10-24 18:15 8103

19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- At the 19th EU-China Business Meeting, co-hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC) in Chengdu, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. (her...

2026-10-24 09:29 8171
123456 ... 380